


1 Autoinducer analogues

1.1 Synthesis of the HHQ derivative

The synthesis of HHQ analogue **26** is shown in Scheme 1 and follows the route devised by Baker.¹ Octonyl chloride **20** was converted to β -ketoester **21** via a Meldrum's acid adduct.^{12,13} The β -ketoester **21** was condensed with *N*-Boc-*p*-phenylenediamine **23** to form enamine **24**. The disappointing yield of this step was in part due to the reaction proceeding to an equilibrium state rather than to completion, and hence not all of the starting material being consumed. Starting materials can be recycled to improve the yield. Alternatively, Baker later found a higher-yielding reaction using a ZrCl_4 catalyst.

The enamine **24** was cyclised with polyphosphoric acid to form amino-HHQ **25** in good yield. The amine group of amino-HHQ **25** was converted to a diazo group by reaction with NaNO_2 and HCl , followed by displacement with NaN_3 to form the final azido-HHQ product **26**.²



Scheme 1: The synthesis of **26**. a) i) Pyridine, DCM, 0°C. ii) MeOH, reflux, 66 % over two steps. b) MeOH, reflux, 19 %. c) Polyphosphoric acid, 120°C, 72 %. d) i) NaNO_2 , HCl , H_2O , 0 °C. ii) NaN_3 , H_2O , r.t., 46.5 %.

azide
step


1.2 PQS derivative

1.2.1 Retrosynthesis of PQS derivative **36**

The retrosynthesis of PQS analogue **36** is shown in Scheme 2. The synthesis of 1-chlorononan-2-one **31** from heptyl magnesium bromide **28**³ and the Weinreb amide **30**⁴ prepared from chloroacetyl chloride **29** has been previously described by Hodgkinson *et al.*³ The synthesis of PQS described by Hodgkinson *et al.*³ uses a microwave reaction of 1-chlorononan-2-one **31** with anthranillic acid. It was hoped that the azide group could be installed by using 5-nitroanthranillic acid **32** in the place of anthranillic acid in this microwave reaction, so that the nitro group could then be converted to an azide group via an amine. However, the microwave-catalysed reaction fails when 5-nitroanthranillic acid **32** is used.⁵ Therefore, a two step process is employed instead. Firstly, ester **33** is formed by $\text{S}_{\text{N}}2$ displacement of the chlorine atom of 1-chlorononan-2-one **31** by the carboxylate group of 5-nitroanthranillic **32**. The ester **33** is then cyclised using a polyphosphoric acid-catalysed

| Conditions | Outcome |
|---|---------------------------------|
| SnCl ₂ ·2H ₂ O, MeOH, r.t., 18 h | No reaction |
| H ₂ , Pd/C, MeOH, 3 atm, r.t., 4 h. | Product 35 , 100 % yield |
| H ₂ , PtO ₂ , MeOH, 1 atm, r.t., 45 min | Product 35 , 80 % yield |

Table 2: Conditions attempted for the synthesis of **35**.




Scheme 3: The synthesis of **36**. a) Mg turnings, THF, r.t., 2 h then reflux, 2 h. b) *N,O*-dimethylhydroxylamine hydrochloride, K₂CO₃, toluene, H₂O, - 5 °C to r.t., 30 min, 71 %. c) THF, 0 °C to r.t., 15 h, 96 %. d) **32**, K₂CO₃, DMF, 90 °C, 1 h, then **31**, r.t., 18 h, 100 %. e) Polyphosphoric acid, 90 °C, 5.5 h, 40 %. f) H₂, PtO₂, MeOH, 1 atm, r.t., 45 min, 80 %. g) i) NaNO₂, HCl, H₂O, 0 °C, 50 min. ii) NaN₃, H₂O, r.t., 4 h, 28 % over two steps.

1.3 C₄-HSL derivatives


1.3.1 Retrosynthesis of C₄-HSL derivatives **41**, **46** and **47**

The azido analogue of C₄-HSL with a C₂ chain **41** (see ??) has previously been prepared by Stacey *et al.*¹¹ It uses the cyclisation of L-methionine **37** using bromoacetic acid via the mechanism shown in Scheme 4 to form the homoserine lactone HBr salt **38**. This is then converted by a biphasic one-pot process to the azido-C₂ analogue **41** using bromoacetyl bromide **39** and NaN₃. It was hoped that this procedure could also be used to

produce the azido-C₄ and C₆ chain analogues.



Scheme 4: The mechanism of formation of **38**.




Scheme 5: The retrosynthesis of **41**, **46** and **47**.

1.3.2 Synthesis of C₄-HSL derivatives **41**, **46** and **47**


Homoserine lactone HBr salt **38** was synthesised using the procedure developed by Stacey *et al.*,¹¹ followed by conversion to the azido-C₂ analogue **41** (see Scheme 6). Attempts to convert homoserine lactone **37** to the azido-C₄ analogue using 4-bromobutyryl chloride **42** produced a complex mixture of products. This is likely to be because the S_N2 reaction where the azide anion displaces bromine is slower as the bromine atom being displaced is no longer next to a carbonyl group. Hence, this allows more side reactions to occur instead of the desired reaction. It was therefore decided that the conversion should be carried out as a two-step process, where a bromoacyl chain is first installed, followed by the S_N2 reaction with NaN₃ (see Scheme 7).

Reaction of the homoserine lactone HBr salt **38** with 4-bromobutyryl chloride **42** or 6-bromohexanoyl chloride **43** produced bromo-C₄ analogue **44** or bromo-C₆ analogue **45** respectively. Heating with NaN₃ in DMF converted bromo-C₆ analogue **45** to azido-C₆ analogue **47**.¹² It is hoped that the same conditions can be used to convert bromo-C₄ analogue **44** to azido-C₄ analogue **46** and this will be attempted shortly.

got
from
Bin Yu




Scheme 6: The synthesis of **41**. a) Bromoacetic acid, *i*-PrOH:H₂O:AcOH (5:5:2), r.t., 18 h, 41 %. b) NaN₃, NaHCO₃, H₂O/CH₂Cl₂, r.t., 18 h, 41 %.



Scheme 7: The synthesis of **46** and **47**. a) Bromoacetic acid, *i*-PrOH:H₂O:AcOH (5:5:2), r.t., 18 h, 41 %. b) NaHCO₃, H₂O/CH₂Cl₂, r.t., 18 h, **44** : 80 %, **45** : 66 %. c) NaN₃, DMF, 100 °C, 5 h, **47** : 56 %.

1.4 Methyl 3-oxodecanoate **21/22**



Meldrum's acid (9.0 g, 63 mmol, 1 eq.) was dissolved in anhydrous CH_2Cl_2 (150 ml) in an oven-dried flask and cooled to 0 °C. Pyridine (10.2 ml, 126 mmol, 2 eq.) was added dropwise over 20 min. Octanoyl chloride (11.7 ml, 69 mmol, 1.1 eq.) was then added and the mixture was stirred at 0 °C for a further 4 h. The mixture was allowed to warm to r.t., diluted with CH_2Cl_2 (20 ml) and poured into a mixture of ice (~30 g) and HCl (2 N, 90 ml). The solution was washed with NaCl (sat., aq., 150 ml) and dried over MgSO_4 . The solvent was removed under vacuum to give an orange-brown oil. The oil was refluxed in anhydrous MeOH (150 ml) for 5 h and the solvent was removed under vacuum. The resulting residue was purified by column chromatography (SiO_2 , 5 % Et_2O /40-60 P.E.). A tautomeric mixture of **21** and **22** was obtained as a colourless oil (8.34 g, 41.6 mmol, 66 %, 92 % **21** as determined by ^1H NMR).

Keto form **21**

TLC R_f = 0.12 (5 % EtO_2 /PE)

IR (neat) ν_{\max} / cm^{-1} = 2927.8 (C-H), 2856.3 (C-H), 1746.9 (ester C=O), 1716.7 (ketone C=O)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 3.74 (s, 3 H, OCH_3), 3.45 (s, 2 H, $\text{C(=O)CH}_2\text{C(=O)}$), 2.53 (t, J = 7.4 Hz, 2 H, $\text{C(=O)CH}_2\text{CH}_2$), 1.60 (quin, J = 7.1 Hz, 2 H, $\text{C(=O)CH}_2\text{CH}_2$), 1.39 - 1.19 (m, 8 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.88 (t, J = 6.8 Hz, 3 H, CH_2CH_3)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 202.3 ($\text{CH}_3\text{OC(=O)CH}_2\text{C(=O)}$), 167.3 ($\text{CH}_3\text{OC(=O)CH}_2\text{C(=O)}$), 51.7 (OCH_3), 48.5 ($\text{CH}_3\text{OC(=O)CH}_2\text{C(=O)}$), 42.5 ($\text{C(=O)CH}_2\text{CH}_2$), 31.3 (CH_2), 28.7 (CH_2), 28.6 (CH_2), 23.1 (CH_2), 22.2 (CH_2), 13.6 (CH_2CH_3)

Enol form **22**

TLC R_f = 0.12 (5 % EtO_2 /PE)


IR (neat) ν_{\max} / cm^{-1} = 2927.8 (C-H), 2856.3 (C-H), 1653.8 (C=C), 1629.2 (α,β unsaturated C=O)

^1H NMR (400 MHz, CDCl_3) δ / ppm = 12.02 (s, 1 H, COH), 4.99 (s, 1 H, C(=O)CH=COH), 3.73 (s, 3 H, OCH_3), 2.20 (t, J = 7.4 Hz, 2 H, COHCH_2), 1.76 - 1.72 (m, 2 H, $\text{COHCH}_2\text{CH}_2$), 1.39 - 1.19 (m, 8 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.88 (t, J = 6.8 Hz, 3 H, CH_2CH_3)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 178.7 ($\text{CH}_3\text{OC(=O)CH=COH}$), 172.7 ($\text{CH}_3\text{OC(=O)CH=COH}$), 88.2 ($\text{CH}_3\text{OC(=O)CH=COH}$), 50.5 (OCH_3), 37.9 ($\text{COHCH}_2\text{CH}_2$), 34.6 (CH_2), 31.2 (CH_2), 29.0 (CH_2), 25.9 (CH_2), 22.3 (CH_2), 13.6 (CH_2CH_3)

Spectroscopic data are consistent with the literature.^{12,13}

1.5 Methyl (*E*)-3-((4-((*tert*-butoxycarbonyl)amino)phenyl)amino)dec-2-enoate **24**



Methyl 3-oxodecanoate **21** (500 mg, 2.50 mmol, 1.00 eq.) and *O*-*tert*-butyl *N*-(4-aminophenyl)carbamate **90** (520 mg, 2.50 mmol, 1.00 eq.) were dissolved in MeOH (10 ml) and refluxed for 18 h. The solvent was removed under vacuum and the resulting residue was purified by column chromatography (SiO₂, gradient of 0 to 20 % Et₂O/40-60 P.E.). **24** was obtained as a white amorphous solid (0.169 mg, 0.480 mmol, 19 %).

TLC R_f = 0.30 (30 % Et₂O/40-60 P.E.)

mp T / °C = 78.8 (Et₂O/40-60 P.E.)

IR (neat) ν_{max} / cm⁻¹ = 3337.0 (N-H), 2927.7 (C-H), 2857.1 (C-H), 1723.7 (carbamate C=O), 1634.5 (α,β unsaturated C=O), 1610.7 (C=C), 1580.9 (N-H bend)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 10.16 (s, 1 H, NH(C₇H₁₅)=C), 7.35 (d, J = 8.6 Hz, 2 H, *meta* to NHBoc), 7.02 (d, J = 8.7 Hz, 2 H, *meta* to enamine), 6.60 (br s, 1 H, NHBoc), 4.71 (s, 1 H, C=CH), 3.70 (s, 3 H, OCH₃), 2.23 (t, J = 7.7 Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.54 (s, 9 H, C(CH₃)₃), 1.40 (quin, J = 7.3 Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.33 - 1.16 (m, 8 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 0.86 (t, J = 7.1 Hz, 3 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 171.1 (C(=O)CH=C), 164.3 (C(=O)CH=C), 152.7 (OC(=O)NH), 136.0 (*para* to NHBoc), 134.1 (CNHBoc), 126.3 (*meta* to NHBoc), 119.1 (*ortho* to NHBoc), 83.8 (C(=O)CH=C), 80.7 (C(CH₃)₃), 50.2 (OCH₃), 32.2 (CH₂), 31.6 (CH₂), 29.1 (CH₂), 28.8 (CH₂), 28.3 (C(CH₃)₃), 28.0 (CH₂), 22.6 (CH₂), 14.0 (CH₃)

HRMS (ESI⁺) m/z / Da = 391.2589, [M+H]⁺, [C₂₂H₃₅N₂O₄]⁺ requires 391.2591

Spectroscopic data are consistent with the literature.¹

1.6 6-Amino-2-heptylquinolin-4-ol **25**



Methyl (*E*)-3-((4-((*tert*-butoxycarbonyl)amino)phenyl)amino)dec-2-enoate **24** (168 mg, 0.649 mmol, 1 eq.) and polyphosphoric acid (5 g) were heated to 90 °C for 1 h. The reaction mixture was then poured into NaHCO₃ (sat., aq., 50 ml) cooled with ice. The precipitate was collected by vacuum filtration, washed with water (50 ml) and dried under high vacuum. **25** was obtained as a pale yellow powder (121 mg, 0.468 mmol, 72 %).

mp $T / ^\circ\text{C} = 249$ (H_2O)

IR (neat) $\nu_{\max} / \text{cm}^{-1} = 3336.5$ (N-H), 2926.5 (C-H), 2856.9 (C-H), 1723.9 (C=O), 1634.5 (aromatic), 1610.8 (aromatic), 1583.3 (aromatic), 1519.1 (aromatic)


^1H NMR (400 MHz, DMSO-d_6) $\delta / \text{ppm} = 7.26$ (d, $J = 8.7$ Hz, 1 H, *meta* to NH_2), 7.15 (d, $J = 2.6$ Hz, 1 H, *ortho* to C(=O)), 6.95 (dd, $J = 2.7, 8.8$ Hz, 1 H, *para* to C(=O)), 5.74 (s, 1 H, *ortho* to CH_2), 5.16 (s, 2 H, NH_2), 2.52 (t, $J = 7.4$ Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.64 (quin, $J = 7.6$ Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 1.36 - 1.19 (m, 8 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.86 (t, $J = 7.0$ Hz, 3 H, H_3)

^{13}C NMR (101 MHz, DMSO-d_6) $\delta / \text{ppm} = 176.7$ (C(=O)), 151.7 (CCH_2), 145.1 (*para* to NH_2), 132.4 (*ipso* to NH_2), 126.6 (*para* to CH_2), 121.1 (*para* to C(=O)), 119.0 (*meta* to NH_2 and *meta* to C(=O)), 106.2 ($\text{CH}=\text{CCH}_2$), 105.9 (*ortho* to NH_2 and *ortho* to C(=O)), 33.6 (CCH_2), 31.6 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 29.0 (CH_2), 29.0 (CH_2), 28.9 (CH_2), 22.5 (CH_2CH_3), 14.4 (CH_3)

HRMS (ESI^+) $m/z / \text{Da} = 259.1810$, $[\text{M}+\text{H}]^+$, $[\text{C}_{16}\text{H}_{23}\text{N}_2\text{O}]^+$ requires 259.1803

Spectroscopic data are consistent with the literature.¹

1.7 6-Azido-2-heptylquinolin-4-ol **26**



6-Amino-2-heptylquinolin-4-ol **25** (50 mg, 0.194 mmol, 1 eq) was dissolved in HCl (conc., aq., 1.20 ml), water (1.80 ml) and MeOH (2.00 ml) and cooled to 0°C . A solution of NaNO_2 (16.0 mg, 0.232 mmol, 1.2 eq.) in water (0.300 ml) was added dropwise over 10 min and the mixture was stirred for 1 h. A solution of NaN_3 (15.1 mg, 0.232 mmol, 1.2 eq.) in water (0.300 ml) was then added. The mixture was warmed to room temperature and stirred for a further 4 h. The resultant precipitate was filtered off and dried under reduced pressure. **26** was obtained as a pale cream amorphous solid (25.6 mg, 0.0900 mmol, 46.5 %).

TLC $R_f = 0.40$ (5 % $\text{MeOH}/\text{CH}_2\text{Cl}_2$)

IR (neat) $\nu_{\max} / \text{cm}^{-1} = ??$

^1H NMR (400 MHz, MeOD) $\delta / \text{ppm} = 7.73$ (d, $J = 8.6$ Hz, 1 H, *ortho* to NH), 7.71 (d, $J = 2.8$ Hz, 1 H, *ortho* to N_3 and *ortho* to C(=O)), 7.47 (dd, $J = 8.9, 2.7$ Hz, 1 H, *para* to C(=O)), 6.24 (s, 1 H, C(=O) CH), 2.69 (t, $J = 7.7$ Hz, 2 H, NHCCH_2), 1.68 (quin, $J = 7.6$ Hz, 2 H, $\text{NHCCH}_2\text{CH}_2$), 1.28 - 1.39 (m, 4 H, $\text{NHCCH}_2\text{CH}_2\text{CH}_2\text{CH}_2$), 1.18 - 1.28 (m, 4 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 0.85 (t, $J = 6.8$ Hz, 3 H, CH_3)


^{13}C NMR (101 MHz, MeOD) $\delta / \text{ppm} = 172.3$ (C(=O)), 155.5 (NHCCH_2), 137.4 (CN_3), 135.6 (*para* to N_3), 124.6 (*para* to C(=O)), 124.1 (*ipso* to C(=O)), 120.7 (*meta* to N_3 and *meta* to C(=O)), 112.8 (*ortho* to N_3 and *ortho* to C(=O)), 107.0 (C(=O) CH), 33.3 (NHCCH_2), 31.2 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 28.3 - 28.5 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$), 22.1 (CH_2CH_3), 14.0 (CH_3)

HRMS (ESI⁺) m/z / Da = ??, [M+H]⁺ found, [??]⁺ requires ??

Spectroscopic data are not consistent with the literature.¹


???

1.8 Heptyl magnesium bromide 28



Magnesium turnings (352 mg, 14.5 mmol, 1 eq.) were added to an oven-dried flask under argon. THF (15 ml) was added, followed by bromoheptane (2.40 ml, 14.5 mmol, 1 eq.) dropwise. The mixture was stirred at r.t. for 2 h followed by heating to reflux for 2 h to give the Grignard reagent as a pale grey suspension (15 ml, ~ 1 M) which was used without further purification.

1.9 2-Chloro-*N*-methoxy-*N*-methylacetamide 30



N,*O*-Dimethylhydroxyl amine hydrochloride (6.00 g, 61.5 mmol, 1 eq.) and toluene (75 ml) were added successively to a stirred solution of potassium carbonate (22.4 g, 162 mmol, 2.63 eq.) in water (75 ml) at 0 °C under argon. The mixture was cooled to - 5 °C and chloroacetyl chloride (5.88 ml, 73.8 mmol, 1.20 eq.) was added dropwise over 5 min. The mixture was allowed to warm to r.t. over 30 min, then the organic layer was separated and the aqueous layer was extracted with toluene (3×20 ml). The combined organic extracts were dried with MgSO₄ and the solvent was removed by rotary evaporation followed by high vacuum. **30** was obtained as white, prism-like crystals (7.24 g, 52.6 mmol, 71 %).

mp T / °C = 38.8 (toluene)


IR (neat) ν_{max} / cm⁻¹ = 3016.7 (C-H), 2966.4 (C-H), 2946.7 (C-H), 2827.7 (C-H), 1666.2 (C=O)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 4.20 (s, 2 H, ClCH₂C=O), 3.71 (m, 3 H, OCH₃), 3.18 (s, 3 H, NCH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 167.4 (C=O), 61.6 (OCH₃), 40.9 (ClCH₂C=O), 32.6 (NCH₃)

Spectroscopic data are consistent with the literature.⁴

1.10 1-Chlorononan-2-one 31



2-Chloro-*N*-methoxy-*N*-methylacetamide (1.00 g, 7.26 mmol, 1 eq.) was added to a dry flask under argon. THF (20 ml) was added and the flask cooled to 0 °C. Heptyl magnesium bromide (~ 1 M, 15.0 ml, 15.0 mmol, 2.07

eq.) was added dropwise over 5 min, then the mixture was allowed to warm to r.t. and stirred for 15 h. The reaction mixture was then poured into HCl (aq., 2 N, 60 ml) at 0 °C and stirred for 10 min. The mixture was extracted with toluene (30 ml) and the aqueous layer discarded. The organic layer was washed with brine and dried with MgSO₄, and the solvent was removed by rotary evaporation. **31** was obtained as a colourless oil (1.23 g, 6.96 mmol, 96 %).


IR (neat) ν_{max} / cm⁻¹ = 2951.7 (C-H), 2925.0 (C-H), 2855.5 (C-H), 1720.4 (C=O)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 4.05 (s, 2 H, ClCH₂C(=O)), 2.54 (t, J = 7.4 Hz, 2 H, C(=O)CH₂CH₂), 1.59 (quin, J = 7.0 Hz, 2 H, C(=O)CH₂CH₂), 1.34 - 1.21 (m, 8 H, CH₂CH₂CH₂CH₂CH₃), 0.87 (t, J = 6.8 Hz, 3 H, CH₃)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 202.6 (C(=O)), 48.1 (CH₂Cl), 39.6 (C(=O)CH₂CH₂), 31.5 (CH₂CH₂CH₃), 28.9 (CH₂), 28.9 (CH₂), 23.5 (C(=O)CH₂CH₂), 22.5 (CH₂CH₃), 13.9 (CH₃)

Spectroscopic data are consistent with the literature.⁴

1.11 2-Oxononyl 2-amino-5-nitrobenzoate **33**



5-Nitroanthranilic acid **32** (500 mg, 2.75 mmol, 1.38 eq.) and potassium carbonate (270 mg, 2.00 mmol, 1 eq.) were dissolved in DMF (5 ml). The mixture was heated under argon to 90 °C and stirred for 1 h then cooled to r.t.. 1-chlorononan-2-one **31** (353 mg, 2.00 mmol, 1 eq.) was added and the mixture was stirred for 15 h. The solution was poured into Na₂HCO₃ (aq., 10 %, 50 ml) and ice (~ 20 g). The precipitate was collected by vacuum filtration, washed with water and dried under high vacuum. **33** was obtained as a yellow amorphous solid (0.674 g, 2.00 mmol, 100 %).

mp T / °C = 135 (H₂O)

IR (neat) ν_{max} / cm⁻¹ = 3453.3 (N-H), 3350.5 (N-H), 2924.9 (C-H), 2853.9 (C-H), 1720.1 (ester C=O) 1703.9 (ketone C=O) 1626.1 (N-H bend) 1602.7 (aromatic) 1572.5 (N-O) 1506.6 (N-O)


¹H NMR (400 MHz, DMSO-d₆) δ / ppm = 8.66 (d, J = 2.8 Hz, 1 H, *ortho* to C(=O)), 8.12 (dd, J = 2.8, 9.4 Hz, 1 H, *para* to C(=O)), 6.93 (d, J = 9.4 Hz, 1 H, *meta* to C(=O)), 5.05 (s, 2 H, OCH₂C(=O)), 2.49 (t, J = 7.4 Hz, 2 H, C(=O)CH₂CH₂), 1.52 (quin, J = 7.2 Hz, 2 H, C(=O)CH₂CH₂), 1.32 - 1.20 (m, 8 H, CH₂CH₂CH₂CH₂CH₃), 0.86 (t, J = 6.8 Hz, 3 H, CH₃)

¹³C NMR (101 MHz, DMSO-d₆) δ / ppm = 204.4 (OCH₂C(=O)), 165.6 (C(=O)O), 156.3 (*ipso* to NH₂), 135.7 (*ipso* to NO₂), 129.6 (*para* to C(=O)), 128.9 (*ortho* to C(=O)), 117.4 (*meta* to C(=O)), 107.5 (*ipso* to C(=O)), 68.8 (OCH₂C(=O)), 38.3 (C(=O)CH₂CH₂), 31.6 (CH₂CH₂CH₃), 28.9 (CH₂), 28.9 (CH₂), 23.2 (C(=O)CH₂CH₂), 22.5 (CH₂CH₃), 14.4 (CH₃)

HRMS (ESI⁺) m/z / Da = 323.1610, [M+H]⁺, [C₁₆H₂₃N₂O₅]⁺ requires 323.1607

Spectroscopic data are consistent with the literature.¹

1.12 6-Nitro-2-heptyl-3-hydroxyquinolin-4(1*H*)-one **34**



2-Oxononyl 2-amino-5-nitrobenzoate (100 mg, 0.340 mmol, 1 eq.) and polyphosphoric acid (300 mg) were stirred for 5.5 h at 90 °C under argon. The mixture was then poured into NaHCO₃ (sat., aq., 50 ml) cooled on ice. The precipitate was collected by vacuum filtration, washed with water (50 ml) and dried under high vacuum. **34** was obtained as a yellow-brown amorphous solid (44 mg, 0.145 mmol, 43 %).

mp $T / ^\circ\text{C} = 223$ (H₂O, EtOAc)

IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3436.0$ (N-H), 3000.0 (O-H, br), 2955.4 (C-H), 2925.8 (C-H), 2850.9 (C-H), 1648.2 (C=O), 1606.1 (aromatic), 1570.7 (N-O), 1536.4 (N-O)


¹H NMR (400 MHz, DMSO-*d*₆) $\delta / \text{ppm} = 12.00$ (s, 1 H, NH), 8.91 (d, $J = 2.8$ Hz, 1 H, *ortho* to C=O), 8.29 (dd, $J = 2.7, 9.2$ Hz, 1 H, *para* to C=O), 7.70 (d, $J = 9.3$ Hz, 1 H, *meta* to C=O), 2.75 (t, $J = 7.7$ Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.67 (quin, $J = 7.3$ Hz, 2 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 1.36 - 1.23 (m, 8 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃), 0.85 (t, $J = 7.0$ Hz, 3 H, CH₂CH₂CH₂CH₂CH₂CH₂CH₃)

¹³C NMR (101 MHz, DMSO-*d*₆) $\delta / \text{ppm} = 169.7$ (C=O), 141.9 (COH), 140.7 (*para* to NO₂), 139.6 (CNO₂), 137.3 (CHC=O), 124.3 (*ortho* to NO₂ and *ortho* to C=O), 122.3 (*ortho* to NO₂ and *para* to C=O), 121.5 (CCH₂CH₂CH₂CH₂CH₂CH₂CH₃), 120.0 (*meta* to NO₂ and *meta* to C=O), 31.6 (CH₂), 29.2 (CH₂), 28.9 (CH₂), 28.5 (CCH₂), 28.1 (CCH₂CH₂), 22.5 (CH₂CH₃), 14.4 (CH₃)

HRMS (ESI⁺) $m/z / \text{Da} = 305.1501$, [M+H]⁺, [C₁₆H₂₁N₂O₄]⁺ requires 305.1500

Spectroscopic data are consistent with the literature.¹

1.13 (*S*)-3-Aminodihydrofuran-2(3*H*)-one hydrobromide **38**



L-Methionine (3.04 g, 20.4 mmol, 1 eq.) and bromoacetic acid (3.08 g, 22.2 mmol, 1.09 eq.) were dissolved in *i*-PrOH (12.5 ml), H₂O (12.5 ml) and AcOH (5 ml). The reaction was refluxed for 15 h then concentrated under vacuum. The resulting brown oil was added to a mixture of *i*-PrOH (16 ml) and HBr (33 % in AcOH, 4 ml), causing the precipitation of a pale pink powder. The precipitate was collected by filtration and washed with *i*-PrOH (20 ml). The filtrate was concentrated under vacuum and precipitated again using the same procedure. The two crops of precipitate were combined. **38** was obtained as a pale pink amorphous solid (1.73 g, 9.50 mmol,

41 % yield).

mp $T / ^\circ\text{C} = 242$ (*i*-PrOH/AcOH, gas evolved)

IR (neat) $\nu_{\max} / \text{cm}^{-1} = 2972.1$ (N-H), 2877.5 (N-H), 1771.8 (C=O), 1585.1 (N-H bend), 1572.2 (N-H bend)


^1H NMR (400 MHz, DMSO- d_6) $\delta / \text{ppm} = 8.59$ (br s, 3 H, NH_3^+), 4.46 (dt, $J = 1.3, 8.9$ Hz, 1 H, OCHH), 4.37 (dd, $J = 8.8, 11.4$ Hz, 1 H, CHNH_3^+), 4.29 (ddd, $J = 6.1, 8.8, 10.9$ Hz, 1 H, OCHH), 2.57 (dddd, $J = 1.2, 6.1, 8.9, 12.3$ Hz, 1 H, OCH_2CHH), 2.26 (dtd, $J = 9.0, 11.2, 12.2$ Hz, 1 H, OCH_2CHH)

^{13}C NMR (101 MHz, DMSO- d_6) $\delta / \text{ppm} = 173.3$ ($\text{C}=\text{O}$), 66.2 (OCH_2), 47.8 (CHNH_3^+), 27.0 (OCH_2CH_2)

$[\alpha]_D^{20} / ^\circ 10^{-1} \text{cm}^2 \text{g}^{-1} = -30.0$ ($c / \text{g}(100 \text{ ml})^{-1} = 0.0200$, DMSO)

The data are consistent with the literature.¹¹

1.14 (*S*)-2-Bromo-*N*-(2-oxotetrahydrofuran-3-yl)acetamide **40**



(*S*)-3-Aminodihydrofuran-2(3*H*)-one hydrobromide **38** (100 mg, 0.549 mmol, 1.08 eq.) and NaHCO_3 (84.9 mg, 1.01 mmol, 2.00 eq.) were dissolved in CH_2Cl_2 (2 ml) and H_2O (2 ml). Bromoacetyl bromide (44.0 μL , 102 mg, 0.505 mmol, 1.00 eq.) was then added dropwise. The reaction mixture was stirred for 24 h, after which the CH_2Cl_2 was removed under vacuum. The aqueous phase was extracted with EtOAc (4 \times 10 ml). The combined organic layers were dried with MgSO_4 and the solvent was removed under reduced pressure. **40** was obtained as white, needle-like crystals (88.0 mg, 0.396 mmol, 74 %).

mp $T / ^\circ\text{C} = 132$ (EtOAc)

IR (neat) $\nu_{\max} / \text{cm}^{-1} = 3255.7$ (N-H), 3066.6 (C-H), 1763.0 (lactone C=O), 1658.0 (amide C=O), 1552.7 (N-H bend)

^1H NMR (400 MHz, CDCl_3) $\delta / \text{ppm} = 6.94$ (br s, 1 H, NH), 4.57 (ddd, $J = 11.7, 8.6, 5.9$ Hz, 1 H, CHNH), 4.51 (td, $J = 9.2, 1.0$ Hz, 1 H, OCHH), 4.32 (ddd, $J = 11.3, 9.4, 5.9$ Hz, 1 H, OCHH), 3.93 (s, 1 H, CHHBr), 3.93 (s, 1 H, CHHBr), 2.87 (dddd, $J = 12.6, 8.6, 5.9, 1.3$ Hz, 1 H, OCH_2CHH), 2.22 (dtd, $J = 12.6, 11.5, 11.5, 8.9$ Hz, 1 H, OCH_2CHH)


^{13}C NMR (101 MHz, CDCl_3) $\delta / \text{ppm} = 174.6$ ($\text{OC}=\text{O}$), 166.4 ($\text{C}(=\text{O})\text{NH}$), 66.1 (OCH_2), 49.8 ($\text{CHNHC}=\text{O}$), 29.9 (OCH_2CH_2), 28.2 ($\text{O}=\text{CCH}_2\text{Br}$)

HRMS The compound does not ionise.

$[\alpha]_D^{20} / ^\circ 10^{-1} \text{cm}^2 \text{g}^{-1} = 27.0$ ($c / \text{g}(100 \text{ ml})^{-1} = 0.00740$, CHCl_3)

The data are consistent with the literature.^{11,14}

1.15 (*S*)-2-Azido-*N*-(2-oxotetrahydrofuran-3-yl)acetamide **41**



(*3S*)-2-Oxotetrahydrofuran-3-aminium bromide **38** (100 mg, 0.552 mmol, 1.08 eq.), NaN₃ (85.7 mg, 1.32 mmol, 2.61 eq.) and NaHCO₃ (84.9 mg, 1.01 mmol, 2.00 eq.) were dissolved in CH₂Cl₂ (2 ml) and H₂O (2 ml). Bromoacetyl bromide (44.0 μ L, 102 mg, 0.505 mmol, 1.00 eq.) was then added dropwise. The reaction mixture was stirred for 48 h, after which the CH₂Cl₂ was removed under vacuum. The aqueous phase was extracted with EtOAc (4 \times 10 ml). The combined organic layers were dried with MgSO₄ and the solvent was removed under reduced pressure. **41** was obtained as white, needle-like crystals (38.4 mg, 0.209 mmol, 41 %).

mp $T / ^\circ\text{C} = 87$ (EtOAc)

IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3283.5$ (N-H), 2923.3 (C-H), 2853.0 (C-H), 2129.7 (N₃), 1782.9 (lactone C=O), 1661.4 (amide C=O), 1536.8 (N-H bend)

¹H NMR (400 MHz, CDCl₃) $\delta / \text{ppm} = 7.05$ (br d, $J = 6.5$ Hz, 1 H, NH), 4.64 (ddd, $J = 11.6, 8.7, 6.8$ Hz, 1 H, CHNH), 4.48 (td, $J = 9.1, 1.3$ Hz, 1 H, OCHH), 4.30 (ddd, $J = 11.2, 9.2, 6.0$ Hz, 1 H, OCHH), 4.04 (s, 2 H, CH₂N₃), 2.76 (dddd, $J = 12.5, 8.8, 6.0, 1.4$ Hz, 1 H, OCH₂CHH), 2.25 (dtd, $J = 12.5, 11.4, 11.4, 8.9$ Hz, 1 H, OCH₂CHH)


¹³C NMR (101 MHz, CDCl₃) $\delta / \text{ppm} = 174.9$ (OC=O), 167.5 (C=ONH), 66.0 (OCH₂), 52.2 (O=CCH₂N₃), 48.9 (CHNHCO), 29.7 (OCH₂CH₂)

HRMS The compound does not ionise.

$[\alpha]_D^{20} / ^\circ 10^{-1} \text{cm}^2 \text{g}^{-1} = -32.6$ ($c / \text{g}(100 \text{ ml})^{-1} = 0.0430$, DMSO)

The data are consistent with the literature.¹¹

1.16 (*S*)-4-Bromo-*N*-(2-oxotetrahydrofuran-3-yl)butanamide **44**



(*S*)-3-Aminodihydrofuran-2(3*H*)-one hydrobromide **38** (200 mg, 1.10 mmol, 1.00 eq.) and NaHCO₃ (170 mg, 2.02 mmol, 1.84 eq.) were dissolved in CH₂Cl₂ (2 ml) and H₂O (2 ml). Bromobutyl chloride (140 μ L, 224 mg, 1.21 mmol, 1.10 eq.) was then added dropwise. The reaction mixture was stirred for 1 h, after which the CH₂Cl₂ was removed under vacuum. The aqueous phase was extracted with EtOAc (7 \times 5 ml) and the combined organic layers were dried with MgSO₄. The solvent was removed under vacuum to give white crystals which

were recrystallised from EtOAc. **44** was obtained as white, needle-like crystals (219 mg, 0.878 mmol, 80 %).

mp $T / ^\circ\text{C} = 105$ (EtOAc)

IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3307.9$ (N-H), 3073.9 (C-H), 2948.9 (C-H), 1773.7 (lactone C=O), 1643.5 (amide C=O), 1541.4 (N-H bend)

^1H NMR (400 MHz, CDCl_3) $\delta / \text{ppm} = 6.31$ (br d, $J = 5.5$ Hz, 1 H, NH), 4.59 (ddd, $J = 6.2, 8.7, 11.5$ Hz, 1 H, CHNH), 4.48 (dt, $J = 1.2, 8.9$ Hz, 1 H, OCHH), 4.30 (ddd, $J = 5.8, 9.3, 11.3$ Hz, 1 H, OCHH), 3.49 (t, $J = 6.3$ Hz, 2 H, CH_2Br), 2.82 (dddd, $J = 1.3, 5.9, 8.7, 12.5$ Hz, 1 H, OCH_2CHH), 2.47 (t, $J = 7.3$ Hz, 2 H, C(=O)CH_2), 2.26 - 2.15 (m, 3 H, OCH_2CHH and $\text{CH}_2\text{CH}_2\text{Br}$)


^{13}C NMR (101 MHz, CDCl_3) $\delta / \text{ppm} = 175.4$ (OC=O), 172.3 (C(=O)NH), 66.1 (OCH_2), 49.3 (CHNHHC=O), 33.9 (C(=O)CH_2), 33.1 (CH_2Br), 30.3 (OCH_2CH_2), 27.9 ($\text{C(=O)CH}_2\text{CH}_2$)

HRMS The compound does not ionise.

$[\alpha]_D^{26.6} / ^\circ 10^{-1} \text{cm}^2 \text{g}^{-1} = -78$ ($c / \text{g}(100 \text{ ml})^{-1} = 0.0833$, MeOH)

The compound has not been reported previously.

1.17 (*S*)-6-Bromo-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide **45**



(*S*)-3-Aminodihydrofuran-2(3*H*)-one hydrobromide **38** (100 mg, 0.549 mmol, 1.00 eq.) and NaHCO_3 (84.9 mg, 1.01 mmol, 1.84 eq.) were dissolved in CH_2Cl_2 (2 ml) and H_2O (2 ml) at r.t.. Bromohexanoyl chloride (93.0 μL , 130 mg, 0.608 mmol, 1.11 eq.) was then added dropwise. The reaction mixture was stirred for 4 h, after which the CH_2Cl_2 was removed under vacuum. The mixture was then filtered, washed with H_2O (10 ml) and dried under high vacuum. **45** was obtained as white, needle-like crystals (101 mg, 0.362 mmol, 66 %).

mp $T / ^\circ\text{C} = 106$ ($\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$)

IR (neat) $\nu_{\text{max}} / \text{cm}^{-1} = 3300.3$ (N-H), 3067.6 (C-H), 2937.4 (C-H), 2856.7 (C-H), 1784.8 (lactone C=O), 1639.3 (amide C=O), 1539.9 (N-H bend)

^1H NMR (400 MHz, CDCl_3) $\delta / \text{ppm} = 6.09$ (br d, $J = 5.7$ Hz, 1 H, NH), 4.57 (ddd, $J = 5.9, 8.6, 11.6$ Hz, 1 H, CHNH), 4.50 (dt, $J = 1.3, 9.1$ Hz, 1 H, OCHH), 4.31 (ddd, $J = 5.9, 9.3, 11.3$ Hz, 1 H, OCHH), 3.43 (t, $J = 6.7$ Hz, 2 H, CH_2Br), 2.88 (dddd, $J = 1.3, 5.9, 8.6, 12.6$ Hz, 1 H, OCH_2CHH), 2.30 (dt, $J = 1.8, 7.5$ Hz, 2 H, C(=O)CH_2), 2.16 (dtd, $J = 8.9, 11.5, 12.5$ Hz, 1 H, OCH_2CHH), 1.90 (quin, $J = 7.2$ Hz, 2 H, $\text{CH}_2\text{CH}_2\text{Br}$), 1.71 (quin, $J = 7.6$ Hz, 2 H, $\text{C(=O)CH}_2\text{CH}_2$), 1.59 - 1.46 (m, 2 H, $\text{C(=O)CH}_2\text{CH}_2\text{CH}_2$)

^{13}C NMR (101 MHz, CDCl_3) $\delta / \text{ppm} = 175.5$ (OC=O), 173.3 (C(=O)NH), 66.1 (OCH_2), 49.3 (CHNHHC=O), 35.8 (CH_2Br), 33.5 (C(=O)CH_2), 32.3 ($\text{CH}_2\text{CH}_2\text{Br}$), 30.5 (OCH_2CH_2), 27.6 ($\text{C(=O)CH}_2\text{CH}_2$), 24.4 (C(=O)CH_2)


CH₂CH₂)

HRMS (ESI⁺) m/z / Da = 278.0381, [M+H]⁺, [C₁₀H₁₇BrNO₃]⁺ requires 278.0386

$[\alpha]_D^{26.6}$ / °10⁻¹cm²g⁻¹ = -16 (c / g(100 ml)⁻¹ = 0.208, MeOH)

The compound has not been reported previously.

1.18 (*S*)-6-Azido-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide **47**



(*S*)-6-Bromo-*N*-(2-oxotetrahydrofuran-3-yl)hexanamide (80 mg, 0.320 mmol, 1.00 eq.) and NaN₃ (26.3 mg, 0.405 mmol, 1.27 eq.) were heated in DMF (0.5 ml) for 5 h at 100 °C. The reaction mixture was then partitioned between CH₂Cl₂ (5 ml) and H₂O (5 ml). The aqueous phase was extracted twice more with CH₂Cl₂ (2×5 ml) and the organic layers were combined and dried over MgSO₄. The solvent was removed by rotary evaporation followed by high vacuum. **47** was obtained as white, needle-like crystals (42.7 mg, 0.178 mmol, 56 %).

mp T / °C = 90.0 (CH₂Cl₂)

IR (neat) ν_{max} / cm⁻¹ = 3314.0 (N-H), 2931.6 (C-H), 2862.9 (C-H), 2095.1 (N₃), 1775.4 (lactone C=O), 1643.1 (amide C=O), 1547.9 (N-H bend)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 5.96 (d, J = 4.2 Hz, 1 H, NH), 4.54 (ddd, J = 11.7, 8.6, 5.7 Hz, 1 H, CHNH), 4.49 (td, J = 9.1, 1.0 Hz, 1 H, OCHH), 4.30 (ddd, J = 11.3, 9.4, 5.8 Hz, 1 H, OCHH), 3.29 (t, J = 6.9 Hz, 2 H, CH₂N₃), 2.88 (dddd, J = 12.5, 8.6, 5.8, 1.1 Hz, 1 H, OCH₂CHH), 2.28 (t, J = 7.5 Hz, 1 H, C(=O)CHH), 2.28 (t, J = 7.4 Hz, 1 H, C(=O)CHH), 2.14 (dtd, J = 12.3, 11.5, 11.5, 8.8 Hz, 1 H, OCH₂CHH), 1.70 (quin, J = 7.6 Hz, 2 H, CH₂CH₂N₃), 1.63 (quin, J = 7.2 Hz, 2 H, C(=O)CH₂CH₂), 1.38 - 1.49 (m, 2 H, C(=O)CH₂CH₂CH₂)


¹³C NMR (101 MHz, CDCl₃) δ / ppm = 175.4 (OC=O), 172.2 (C(=O)NH), 66.1 (OCH₂), 51.2 (CH₂N₃), 49.4 (CHNHHC=O), 35.9 (C(=O)CH₂), 30.7 (OCH₂CH₂), 28.6 (CH₂CH₂N₃), 26.3 (C(=O)CH₂CH₂), 24.8 (C(=O)CH₂CH₂CH₂)

HRMS (ESI⁺) m/z / Da = 241.1289, [M+H]⁺, [C₁₀H₁₇N₄O₃]⁺ requires 241.1295

$[\alpha]_D^{26.6}$ / °10⁻¹cm²g⁻¹ = -16 (c / g(100 ml)⁻¹ = 0.208, MeOH)

The compound has not been reported previously.

1.19 Hex-5-ynal **49**



Pyridinium chlorochromate (14.6 g, 68.1 mmol, 1.50 eq) and DCM (500 ml) were stirred at r.t. under argon. 5-hexyn-1-ol **48** (5.00 ml, 45.4 mmol, 1 eq.) was added and the reaction mixture was stirred for 5 h followed by addition of Et₂O (125 ml) and silica gel (62.5 g). The suspension was stirred for 1 h then filtered through a pad of silica (100 g) and washed with Et₂O. The solvent was removed by rotary evaporation. **49** was obtained as a pale yellow-green oil (4.72 g, 49.1 mmol, 72 %).


IR (neat) ν_{max} / cm⁻¹ = 3292.7 (alkyne C-H), 2943.3 (alkane C-H), 2830.9 (aldehyde C-H), 2728.6 (aldehyde C-H), 1720.3 (aldehyde C=O)

¹H NMR (400 MHz, CDCl₃) δ / ppm = 9.80 (s, 1 H, C(=O)H), 2.60 (t, J = 7.1 Hz, 2 H, CH₂C(=O)H), 2.26 (dt, J = 2.6, 6.8 Hz, 2 H, HC≡CCH₂), 1.98 (t, J = 2.7 Hz, 1 H, HC≡C), 1.85 (quin, J = 7.0 Hz, 2 H, HC≡CCH₂CH₂)

¹³C NMR (101 MHz, CDCl₃) δ / ppm = 201.6 (C(=O)), 83.1 (HC≡C), 69.3 (HC≡C), 42.4 (CH₂C(=O)), 20.7 (CH₂CH₂C(=O)), 17.6 (HC≡CCH₂)

Spectroscopic data are consistent with the literature.¹⁵

1.20 *tert*-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate **51**



Hex-5-ynal **49** (0.407 g, 4.24 mmol, 1.00 eq.) and *tert*-butyl piperazine-1-carboxylate (0.791 g, 4.24 mmol, 1.00 eq.) were stirred under a N₂ atmosphere in 1,2-dichloroethane (20 ml) for 2.5 h followed by addition of sodium triacetoxyborohydride (6.25 g, 29.5 mmol, 6.96 eq.) in four portions over 4 d. The mixture was stirred for a further day then NaHCO₃ (sat., aq., 120 ml) was added and the product extracted with EtOAc (2×100 ml). The solvent was dried over MgSO₄ and removed by rotary evaporation. **51** was obtained as a colourless liquid (1.12 g, 4.21 mmol, 99 %).

TLC R_f (10 % MeOH/CH₂Cl₂) = 0.55

IR (neat) ν_{max} / cm⁻¹ = 3303.6 (alkyne C-H), 2940.0 (alkane C-H), 2865.2 (C-H), 2810.4 (C-H), 1691.3 (carbamate C=O)


¹H NMR (400 MHz, CDCl₃) δ / ppm = 3.44 (t, J = 5.2 Hz, 4 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 2.39 (t, J = 5.1 Hz, 4 H, CH₂CH₂CH₂N(CH₂)CH₂), 2.37 (t, J = 7.3 Hz, 2 H, CH₂CH₂CH₂N), 2.23 (dt, J = 2.7, 6.8 Hz, 2 H, HC≡CCH₂), 1.96 (t, J = 2.7 Hz, 1 H, HC≡C), 1.65 - 1.53 (m, 4 H, HC≡CCH₂CH₂CH₂), 1.47 (s, 9 H, CH₃)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 154.7 ($\text{NC}(=\text{O})\text{O}$), 84.2 ($\text{HC}\equiv\text{C}$), 79.6 ($\text{C}(\text{CH}_3)_3$), 68.5 ($\text{HC}\equiv\text{C}$), 60.4 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 58.0 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 53.0 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 28.4 ($\text{C}(\text{CH}_3)_3$), 26.3 ($\text{CH}_2\text{CH}_2\text{N}$), 25.7 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2$), 18.3 ($\text{HC}\equiv\text{CCH}_2$)

HRMS (ESI^+) m/z / Da = 267.2073, $[\text{M}+\text{H}]^+$, $[\text{C}_{15}\text{H}_{27}\text{N}_2\text{O}_2]^+$ requires 267.2064

The compound has not been reported previously.

1.21 1-(Hex-5-yn-1-yl)piperazine **52**



tert-Butyl 4-(hex-5-yn-1-yl)piperazine-1-carboxylate **51** (763 mg, 2.86 mmol) was stirred in TFA (10 ml) at r.t. for 2 h. The TFA was removed under vacuum followed by co-evaporation with CH_2Cl_2 (2×20 ml). The oil was diluted with H_2O (10 ml) and the pH adjusted to 14 with NaOH (10 % aq.). This mixture was extracted with CH_2Cl_2 (2×20 ml) and the combined organic layers were dried over MgSO_4 . The solvent was removed under vacuum and purified by column chromatography (SiO_2 MeOH/ CH_2Cl_2 3:7). **52** was obtained as a colourless liquid (476 mg, 2.86 mmol, 100 %).

TLC R_f (30 % MeOH/ CH_2Cl_2) = 0.20

IR (neat) ν_{max} / cm^{-1} = 3295.9 (alkyne C-H), 2941.1 (alkane C-H), 2810.6 (alkane C-H), 1637.2 (N-H bend)


^1H NMR (400 MHz, CDCl_3) δ / ppm = 2.88 (t, J = 4.9 Hz, 4 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 2.39 (m, 4 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 2.31 (t, J = 7.1 Hz, 2 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 2.20 (dt, J = 2.7, 6.8 Hz, 2 H, $\text{HC}\equiv\text{CCH}_2$), 2.05 (br s, 1 H, NH), 1.93 (t, J = 2.7 Hz, 1 H, $\text{HC}\equiv\text{C}$), 1.65 - 1.48 (m, 4 H, $\text{HC}\equiv\text{CCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$)

^{13}C NMR (101 MHz, CDCl_3) δ / ppm = 84.3 ($\text{HC}\equiv\text{C}$), 68.4 ($\text{HC}\equiv\text{C}$), 58.6 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 54.5 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2)\text{CH}_2$), 46.0 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)\text{CH}_2\text{CH}_2$), 26.4 ($\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$), 25.7 ($\text{HC}\equiv\text{CCH}_2\text{CH}_2$), 18.3 ($\text{HC}\equiv\text{CCH}_2$)

HRMS (ESI^+) m/z / Da = 167.1548, $[\text{M}+\text{H}]^+$, $[\text{C}_{10}\text{H}_{19}\text{N}_2]^+$ requires 167.1548

The compound has not been reported previously.

1.22 1-Cyclopropyl-6-fluoro-7-(4-(hex-5-yn-1-yl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **92**



7-Chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid **53** (1.27 g, 4.51 mmol, 1 eq.), 1-(hex-5-yn-1-yl)piperazine **52** (1.5 g, 9.02 mmol, 2 eq.) and *N*-methyl-2-pyrrolidone (10 ml) were stirred in a microwave reactor at 115 °C for 24 h. The reaction mixture was cooled to r.t. and water (80 ml) was added. The mixture was stirred for 3 h and then filtered, and residue was washed with MeOH (50 ml). The resulting solid (0.571 g) was further purified by recrystallisation from EtOAc (50 ml). **92** was obtained as off-white crystals (0.219 g, 0.531 mmol, 11.8 %).

TLC R_f = 0.02 (10 % MeOH/CH₂Cl₂)

mp T / °C = 220 (MeOH, decomposes)

IR (neat) ν_{max} / cm⁻¹ = 3212.0 (alkyne C-H), 2459.3 (O-H), 1722.6 (carboxylic acid C=O), 1626.8 (quinolone C=O)

¹H NMR (500 MHz, DMSO-d₆) δ / ppm = 15.12 (br s, 1 H, C(=O)OH), 8.69 (s, 1 H, *ortho* to C(=O)OH), 7.96 (d, J = 13.0 Hz, 1 H, *ortho* to F), 7.61 (d, J = 7.6 Hz, 1 H, *meta* to F), 3.82 - 3.92 (m, 3 H, NCH(CH₂)₂ and CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 3.54 - 3.68 (br m, 2 H, CH₂CH₂CH₂N(CH₂)CH₂), 3.45 (br. t, J = 11.6 Hz, 2 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 3.21 - 3.29 (br m, 2 H, CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 3.11 - 3.20 (br m, 2 H, CH₂CH₂CH₂N(CH₂)CH₂), 2.84 (t, J = 2.7 Hz, 1 H, HC≡C), 2.24 (td, J = 7.0, 2.7 Hz, 2 H, HC≡CCH₂), 1.83 (br. quin, J = 7.5 Hz, 2 H, HC≡CCH₂CH₂CH₂), 1.52 (quin, J = 7.4 Hz, 2 H, HC≡CCH₂CH₂), 1.29 - 1.36 (m, 2 H, NCH(CH₂)₂), 1.16 - 1.23 (m, 2 H, NCH(CH₂)₂)

¹³C NMR (126 MHz, DMSO-d₆) δ / ppm = 176.4 (C(=O)CC(=O)OH), 165.8 (C(=O)OH), 152.8 (d, J = 248.5 Hz, *ipso* to F), 148.2 (CHCC(=O)OH), 143.7 (d, J = 11.1 Hz, *para* to C(=O)), 139.1 (*para* to F), 119.4 (d, J = 6.9 Hz, *ipso* to C(=O)), 111.2 (d, J = 22.5 Hz, *ortho* to F and *ortho* to C(=O)), 106.9 (*meta* to F and *meta* to C(=O)), 106.9 (C(=O)CC(=O)OH), 83.9 (HC≡C), 71.8 (HC≡C), 55.0 (CH₂CH₂CH₂N), 50.5 (CH₂CH₂CH₂N(CH₂)CH₂), 46.3 (CH₂CH₂CH₂N(CH₂CH₂)CH₂CH₂), 36.0 (NCH(CH₂)₂), 25.2 (HC≡CCH₂CH₂), 22.3 (HC≡CCH₂CH₂CH₂), 17.4 (HC≡CCH₂), 7.6 (NCH(CH₂)₂)

¹⁹F NMR (376.45 MHz, MeOD) δ / ppm = -121.8 (s, ciprofloxacin F)

HRMS (ESI⁺) m/z / Da = 412.2036, [M+H]⁺, [C₂₃H₂₇N₃O₃F]⁺ requires 412.2030

The compound has not been reported previously.

2 References

- [1] Y. R. Baker. Investigating quinolone based quorum sensing in *Pseudomonas aeruginosa* using a chemical proteomics approach. PhD thesis, University of Cambridge. 2015.
- [2] S. Xu, X. Zhuang, X. Pan, Z. Zhang, L. Duan, Y. Liu, L. Zhang, X. Ren and K. Ding. 1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor α . *Journal of Medicinal Chemistry*, 56:4631–4640. 2013.
- [3] J. T. Hodgkinson, W. R. J. D. Galloway, M. Welch and D. R. Spring. Microwave-assisted preparation of the quorum-sensing molecule 2-heptyl-3-hydroxy-4(1H)-quinolone and structurally related analogs. *Nature Protocols*, 7(6):1184–1192. 2012.
- [4] J. T. Hodgkinson. The synthesis of *Pseudomonas* Quinolone Signal analogues and their effects on quinolone signalling in *Pseudomonas aeruginosa*. PhD thesis, University of Cambridge. 2011.
- [5] Y. Baker. Personal Communication. 2014.
- [6] P. Hradil, J. Hlaváč and K. Lemr. Preparation of 1,2-disubstituted-3-hydroxy-4(1H)-quinolinones and the influence of substitution on the course of cyclization. *Journal of Heterocyclic Chemistry*, 36(1):141–144. 1999.
- [7] P. E. Eaton, G. R. Carlson and J. T. Lee. Phosphorus Pentoxide-Methanesulfonic Acid. A Convenient Alternative to Polyphosphoric Acid. *Journal of Organic Chemistry*, 38(23):4071–4073. 1973.
- [8] D. Zewge, C.-y. Chen, C. Deer, P. G. Dormer and D. L. Hughes. A Mild and Efficient Synthesis of 4-Quinolones and Quinolone Heterocycles makes it difficult to handle for large-scale operations . The lack of a general and mild method led researchers to develop new synthetic strategies that involve an increased number. *Journal of Organic Chemistry*, (13):4276–4279. 2007.
- [9] J. Hlaváč, M. Sural, P. Hradil, I. Frys and J. Slouka. The Cleavage of Heterocyclic Compounds in Organic Synthesis II [1] Use of 5-Nitroisatine for Synthesis of Various Nitrogenous Heterocycles. *Journal of Heterocyclic Chemistry*, 41:633–636. 2004.
- [10] G. Shen, M. Wang, T. R. Welch and B. S. J. Blagg. Design, synthesis, and structure–activity relationships for chimeric inhibitors of Hsp90. *The Journal of Organic Chemistry*, 71(20):7618–7631. 2006.
- [11] D. M. Stacy, S. T. Le Quement, C. L. Hansen, J. W. Clausen, T. Tolker-Nielsen, J. W. Brummond, M. Givskov, T. E. Nielsen and H. E. Blackwell. Synthesis and biological evaluation of triazole-containing N-acyl homoserine lactones as quorum sensing modulators. *Organic & Biomolecular Chemistry*, 11(6):938–954. 2013.
- [12] Y. R. Baker. Novel Affinity Based Probes for Use in Chemical Proteomic Studies. CPGS thesis. University of Cambridge. 2012.
- [13] J. D. Scribner, D. L. Smith and J. A. McCloskey. Meldrum’s Acid in Organic Synthesis. 2. A General and Versatile Synthesis of β -Keto Esters. *The Journal of Organic Chemistry*, 43(10):2087–2088. 1978.
- [14] T. Persson, T. H. Hansen, T. B. Rasmussen, M. E. Skindersø, M. Givskov and J. Nielsen. Rational design and synthesis of new quorum-sensing inhibitors derived from acylated homoserine lactones and natural products from garlic. *Organic & Biomolecular Chemistry*, 3(2):253–262. 2005.
- [15] L. S. Kocsis, E. Benedetti and K. M. Brummond. A Thermal Dehydrogenative Diels-Alder Reaction of Styrenes for the Concise Synthesis of Functionalized Naphthalenes. *Organic Letters*, 14(17):4430–4433. 2012.

Todo list

| | |
|---|---|
| azide step | 1 |
| what are we doing with the last 2 compounds?? | 2 |
| got from Bin Yu | 4 |
| ??? | 9 |